Reactogenicity to the mRNA-1273 Booster According to Previous mRNA COVID-19 Vaccination

Abstract

The objective of this study was to assess the local and systemic adverse reactions after the administration of a COVID-19 mRNA-1273 booster between December 2021 and February 2022 by comparing the type of mRNA vaccine used as primary series (mRNA-1273 or BNT162b2) and homologous versus heterologous booster in health care workers (HCW). A cross-sectional study was performed in HCW at a tertiary hospital in Barcelona, Spain. A total of 17% of booster recipients responded to the questionnaire. The frequency of reactogenicity after the mRNA-1273 booster (88.5%) was similar to the mRNA-1273 primary doses (85.8%), and higher than the BNT162b2 primary doses (71.1%). The reactogenicity was similar after receiving a heterologous booster compared to a homologous booster (88.0% vs. 90.2%, p = 0.3), and no statistically significant differences were identified in any local or systemic reactions. A higher frequency of medical leave was identified in the homologous booster dose group vs. the heterologous booster dose group (AOR 1.45; 95% CI: 1.00–2.07; p = 0.045). Our findings could be helpful in improving vaccine confidence toward heterologous combinations in the general population and in health care workers.

Integration of Cellular and Humoral Immune Responses as an Immunomonitoring Tool for SARS-CoV-2 Vaccination in Healthy and Fragile Subjects

“…Consistently, we observed the same trend in our study population, without detecting differences between the cohorts of HCWs and cancer patients. Regarding the effect of the vaccination boost, several works described a frequency of adverse reactions similar to those identified after the second, affecting about 70–80% of vaccines [ 36 , 37 ]. In this study, the percentage of individuals reporting at least one side effect after the third dose was slightly lower both compared to the literature evidence and the percentage detected after the second dose.…”

Incidence and Nature of Adverse Events Following COVID-19 Second Boosters: Insights from Taiwan's Universal Vaccination Strategy

“…The risk of AE could be repeated, upon subsequent administrations of the same vaccine. Given the variety of COVID-19 vaccines available, each based on different technological platforms such as mRNA and non-replicating viral vectors, potential mechanisms for this could involve immunological responses such as hypersensitivity or immune sensitization, especially relevant in the context of repeated exposures to vaccine antigens [3,13,29]. Moreover, the risk of AE could be cumulative potentially due to cumulative immunological effects or other underlying biological factors.…”

Incidence and Nature of Short-Term Adverse Events following COVID-19 Second Boosters: Insights from Taiwan’s Universal Vaccination Strategy

“…The risk of AEs could be repeated upon subsequent administrations of the same vaccine. Given the variety of COVID-19 vaccines available, each based on different technological platforms such as mRNA and non-replicating viral vectors, potential mechanisms for this could involve immunological responses such as hypersensitivity or immune sensitization, especially relevant in the context of repeated exposures to vaccine antigens [ 3 , 13 , 29 ]. Moreover, the risk of AEs could be cumulative, potentially due to cumulative immunological effects or other underlying biological factors.…”